She developed generalised tonic-colonic seizures at five days of age, which were well controlled with phenobarbitone. Seizures have not been evident beyond the infantile period.
An MRI of the brain at 9 months of age demonstrated a hypoplastic corpus callosum, and reduced white matter. Optic nerve hypoplasia was detected on fundoscopy and was associated with poor visual acuity. Anterior and posterior pituitary endocrine function were intact. Dysmorphic features included depressed nasal bridge, low set and posteriorly rotated ears, square nasal tip, epicanthic folds, mild micrognathia and mild retrognathia, and 2-3 toe syndactyly. Genitalia were normally formed.
Currently she is 10 years of age, and demonstrates profound global developmental delay in all modalities, in keeping with the milestone acquisition of a 6-month old child. She can roll and sit independently. She can manipulate objects to her mouth but is unable to feed herself. She is non-verbal, but does smile in response to verbal social interactions.
Neurological examination demonstrates central hypotonia, hyperreflexia, and fixed flexion joint contractures at the knees. Irritability and autistic-like behaviors, such as habitual eye poking, have been evident since the first year of life. Hypersalivation has required medical interventions. Postnatal failure to thrive, compounded by an unsafe swallow, required the insertion of a PEG at 4 years of age for enteral feeding. Sleep initiation and maintenance are significant issues which have responded to melatonin supplementation. Dry skin and photosensitivity is evident with clinically significant UV sun damage after only 10 minutes in direct sunlight. A skeletal survey demonstrated thin gracile bones with reduced bone mineralization, but no skeletal axial fractures have been observed.
Individual 2
This male infant was delivered via a SVD at 39 weeks gestation after an uneventful pregnancy, with Apgar scores of 9 and 9 at one and five minutes respectively, a birth weight 2750g, head circumference 34cm, and length 49cm. His clinical course has mirrored that of his elder sister. He showed the same brain MRI changes, dysmorphic features, and bilateral undescended testes that required surgical intervention. He is currently 7 years of age, and demonstrates profound global developmental delay in all modalities, with an overall skill acquisition of a 9-month old child. He can sit independently, and pull to stand and will ambulate short distances on his knees. He can babble, smiles in response to verbal social interactions, but does not display meaningful social language.
Individual 3
This male infant was delivered at 39 weeks gestation after an uneventful pregnancy, with Apgar scores of 9 and 9 at one and five minutes respectively, a birth weight 3033grams, head circumference 33cm, and length 50cm. His clinical presentation in infancy was significant for severe static encephalopathy, intractable epilepsy, spasticity, opisthotonos, global developmental delay with cortical blindness, hypospadias, bicuspid aortic valve, neonatal hepatitis, dry skin, facial dysmorphism, failure to thrive and sleep dysfunction. Dysmorphism included coarse facial features, bitemporal narrowing, prominent ears, and triangular facies. (a) PCR results using FDFT1 cDNA generated from Individual 2, with primers in exon 8 and exon 9. Top two lanes show the forward and reverse electropherograms obtained using standard Sanger sequencing. Given the deletion on the maternal allele, cDNA product is only obtained from the paternal allele. The c.880-24_880-23delinsAG variant is predicted to lead to aberrant splicing, characterized by the retention of 22 bases of intron 8 sequence. This aberrantly spliced product will result in a premature termination codon in exon 9, and is therefore expected to be degraded by nonsense mediated mRNA decay (NMD). With the wt splice acceptor still intact, it is expected that normally spliced FDFT1 can also be detected. cDNA analysis of individual 2 indeed shows the normal splice product (from the wt acceptor splice site) as well as a lower, 2 nd trace reflecting the residual aberrant splice product from incomplete NMD. (b) To provide further functional proof that the c.880-24_c.880-23delinsAG variant as observed in Individuals 1 and 2, results in aberrant splicing, a mini-gene splice assay was set up, using sequence of exon 8, intron 8 and exon 9. In a wildtype scenario (left), exon 8 and exon 9 are spliced together. Targeted mutagenesis to introduce the variant shows that indeed aberrant splicing occurs, as is shown by the retention of 22 bases of intron 8 sequence. (-CHX) to differentiate between absence of transcripts due to NMD or due to regulatory effects. Fibroblasts from a control individual were used to determine normal expression patterns of these isoforms in fibroblasts. Also, various organ specific cDNA libraries were tested for the normal expression patterns of these isoforms. (b) Simplified overview of the results presented in (a) using the following codes: +: detected; -: absent; Red: no isoform detection expected based on related control experiment; Yellow: tissues where the respective isoform is normally identified and likely absent in the patient. Figure 4 , and Table S1 .
Supplemental Tables   Table S1: Raw and processed data of luciferase assay for assessing promoter activity of FDFT1 intronic sequence.
Supplemental Methods

Urine organic characterization GC-MS and NMR
Urine organic acids. Urine organic acid screening was performed by standard methodology involving solvent extraction, conversion to trimethylsilyl derivatives and analysis by GC-MS 1 .
Plasma total farnesol and squalene measurements. Two hundred μL plasma was mixed with 200 μL of 100 mM Tris buffer pH 9.5 containing 100 mM sodium chloride and 50 mM Urine NMR. Urine of the three individuals with squalene synthase deficiency was measured with one-dimensional-and 2-dimensional COSY proton NMR spectroscopy at 500 MHz at pH 2.50 via previously described methods 2, 3 Genetic analysis DNA isolation. Genomic DNA was extracted from whole blood using QIAamp DNA Blood Mini Kit (Qiagen, Cat# 69506), following manufacturer's specifications. Genomic DNA (gDNA) was subjected to agarose gel and OD ratio tests to confirm the purity and concentration.
Genome build. For mapping and annotation purposes referred to in this study, genome
Reference Consortium Human Build 37, GRCh37, also known as hg19, was used.
Genomic microarray analysis. Genome-wide array analysis was performed by Mater Pathology
Queensland using the SNP-based Cytoscan 750K array (Affymetix), with an effective resolution of 200 kb for copy number variation and 5 Mb resolution for contiguous stretches of homozygosity. Software analysis was performed using Chromosome Analysis Suite (ChAS) (Affymetrix).
Whole exome sequencing. WES was using DNA isolated from whole blood. For individuals 1 and 2, WES was performed by Otogenetics Corporation (Norcross, GA USA). ) In essence, exome enrichment was based on Agilent SureSelect AV5 Exon Coverage (Agilent Technologies, Wilmington, DE USA, catalog# 5190-6208) following manufacturer's instructions, after which PE sequencing was performed with a read length of 100-106 nucleotidesat, covering 97.7% of targeted regions 100-fold and 99.7% 10-fold.
Analysis pipeline included mapping (hg19) with BWA-MEM and SAMtools, realignment and base calling with GATK Lite (2.3), variants annotation with snpEff and snpSift. The annotated files were further analysed using Genegrid (Genomatix). Only deleterious variants with an allele frequency <0.01 according to the 1000 genomes phase 3 data set and the ExAC data set and shared by both affected siblings were considered candidates. For Individual 3 and his parents a Trio whole exome sequencing was performed commercially by Macrogen (Korea) using the Agilent SureSelect V5 capture kit, and run on an Illumina HiSeq4000 apparatus. The average read length was 101 bp and the mean depth of on-target reads was 92X. Subsequently, variants were filtered for a minor allele frequency <0.1% in ExAC and our in-house database containing 7,788 exomes, and for a strong effect on protein level (e.g.
nonsense, missense, splice site and indels). Notably, after analyzing WES data of Individuals 1 and 2, pointing towards the involvement of FDFT1, all variants in this gene identified were searched for, including those in intronic sequences of FDFT1 captured by WES. The latter filtering identified the private 16-bp homozygous intronic deletion. Due to its proximity to the exon, the intronic variant sequence was captured by the exome capture at a coverage over 10 reads.
Functional validation
Splice site variant analysis. Exon 9 of FDFT1, with flanking exon/intron boundaries, was PCR amplified from control gDNA using primers 5´-AGCAATTGCCCATTCAACAGA-3´ and 5´-ACCTGGTTAAACAGTGACATTACTA-3´. PCR product was cloned into pCR2.1-TOPO for screening and then subcloned into the pEF-1α promoter of p.EZe1.1, to create a wild-type according to the manufacturer's instructions. Cells were harvested 24h post-transfection and RNA extracted using an RNeasy mini kit (Qiagen). cDNA synthesis was performed on 2 µg RNA using SuperScript III reverse transcriptase (Life Technologies). Primers targeted to pEZe1.1 were used to amplify the cDNA region containing the spliced FDFT1 exon 9. Products were analysed by 1.5% (w/v) agarose gel electrophoresis and Sanger sequencing (AGRF).
To assess the effect of the c.880-24_880-23delinsAG mutation at cDNA level in individual 1 and 2, fibroblasts were grown and harvested for mRNA extraction according to standard procedures. A similar procedure was followed using control individuals. Primers designed for the full length of FDFT1 cDNA (1441 bp) failed to produce a product, after which primers were designed to amplify part of the cDNA (993 bp). The relevant PCR products were isolated from gel and purified, after which they were sent for Sanger sequencing.
Western Blot. Immunoblotting and densitometry were performed as previously described 4 isoforms. Unique primers to distinguish NM_001287756.1 from NM_004462.4 could not be made. In addition, organ specific cDNA libraries from fetal and adult tissues were tested for the normal patterns of these isoforms. Obtained PCR products were sequenced to verify the isoform specificity.
Luciferase assay. Gateway-tailed PCR primers (FW: GGGGACAAGTTTGTACAAAAAA GCAGGCTTCCCAAAGTGTTGCGATTACA; RV: GGGGACCACTTTGTACAAGAAAGCTGGGTGATC TTGGGCATCACCTTCC) were used to amplify a 1024 bp genomic PCR product using DNA from a control and individual 3 to assess the promoter activity under normal condition as well as when containing the 16 bp deletion respectively. The promoter sequence was subsequently introduced into entry-vector pDONR201 following the manufacturer's instructions, and transformed into DH5alpha chemically competent cells. Colonies were grown overnight at 37°C after which routine miniprep was performed for plasmid DNA isolation. The DNA insert was sequenced to exclude genetic variation other than the 16-bp deletion. Both the WT 1024 bp sequence as well as the one containing the 16 bp deletion observed in Individual 3, were cloned into pGL3 to perform the luciferase assay. pGL3 containing GPR180 and its relevant transcription were used as technical positive control, whereas an empty pGL3 basic vector was used as negative control. All constructs were co-transfected with Renilla to determine transfection efficiency. Luciferase activity was measured from two biological replicates (100 ng per assay) using luminometry, in triplicate. Relative promoter activity was determined by correcting for transfection efficiency, and normalization against the activity of the empty pGL3 vector.
